Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 2
2007 1
2008 4
2009 2
2010 4
2013 3
2014 5
2015 4
2016 4
2017 1
2018 6
2019 2
2020 4
2021 4
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. Haderk F, et al. Among authors: bandyopadhyay s. Nat Commun. 2024 May 3;15(1):3741. doi: 10.1038/s41467-024-47423-0. Nat Commun. 2024. PMID: 38702301
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. Yu K, et al. Among authors: bandyopadhyay s. Front Oncol. 2023 Jun 13;13:1192208. doi: 10.3389/fonc.2023.1192208. eCollection 2023. Front Oncol. 2023. PMID: 37384294 Free PMC article.
Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Brand TM, et al. Among authors: bandyopadhyay s. Cancer Res. 2022 Sep 2;82(17):3187. doi: 10.1158/0008-5472.CAN-22-1308. Cancer Res. 2022. PMID: 36052496 No abstract available.
Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Brand TM, et al. Among authors: bandyopadhyay s. Cancer Res. 2022 Sep 2;82(17):3188. doi: 10.1158/0008-5472.CAN-22-1307. Cancer Res. 2022. PMID: 36052495 No abstract available.
Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Brand TM, et al. Among authors: bandyopadhyay s. Clin Cancer Res. 2021 Jul 15;27(14):4129. doi: 10.1158/1078-0432.CCR-21-2141. Clin Cancer Res. 2021. PMID: 34261774 No abstract available.
51 results